Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EvasayilTM : A Placebo-controlled Trial to Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton Syndrome

NCT05856526 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05856526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05856526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EvasayilTM : A Placebo-controlled Trial to Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton Syndrome
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2/3
Overall status
Terminated
Start date
June 12, 2023
Completion date
July 31, 2025
Enrollment
43 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

netherton syndrome